The Swiss group does another deal to access a novel technology, taking out the RNAi specialist The Medicines Company.
Alnylam unveils a novel pricing strategy for its second RNAi launch, which was greenlit by the US regulator with notable speed.
Cynosure’s technology seems to have been better at destroying value than it was at destroying fat – Hologic has sold the business for a tenth of the purchase price.
The Dutch group is ripe for a takeover, and while Thermo Fisher has to be the likeliest candidate for acquirer there are a number of potentially interested parties.
The Hero study gives Myovant an opportunity to change the way hormone-sensitive prostate cancer is treated.
Two more Orion trials have hit neatly and cleanly, and now success will be largely down to pricing.
Novo Nordisk takes its first step into RNA with a broad cardio-metabolic deal with Dicerna, the biggest sealed by the US biotech to date.
The healthcare company builder Puretech registers one success and one failure, both underlining the need for robust mid-stage data.
After an overwhelmingly positive adcom, the outstanding question around Vascepa is just how big the product might become.